Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat: A Comparison with Mivacurium

Anesthesiology

Volumn 100, Issue 4, 2004, Pages 835-845

  Savarese, John J ^a   Belmont, Matthew R ^a   Hashim, Mir A ^b   Mook Jr , Robert A ^c   Boros, Eric E ^d   Samano, Vicente ^d   Patel, Sanjay S ^f,g   Feldman, Paul L ^d   Schultz, Jan Ake I ^a   McNulty, Michael ^e   Spitzer, Timothy ^f   Cohn, Douglas L ^h   Morgan, Philip ^i,j   Wastila, William B ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MV CEDD Biology   (United Kingdom)

^c Oncology Chemistry   (United States)

^d MV CEDD Chemistry   (United Kingdom)

^e Discovery Research ^*

^f GLAXOSMITHKLINE   (United Kingdom)

^g Clinical Research   (United States)

^h ALBANY MEDICAL COLLEGE   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j Cytospect Pharma   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AV 430A; CHLORALOSE; CYSTEINE; EDROPHONIUM; FUMARIC ACID DERIVATIVE; GW 280430A; HALOTHANE; HISTAMINE; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; OXYGEN; PENTOBARBITAL; SUXAMETHONIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CAT; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEGRADATION; DRUG MECHANISM; DRUG POTENCY; FLUSHING; HYPOTENSION; MALE; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VAGUS NERVE;

ANIMALS; BLOOD PRESSURE; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; ISOQUINOLINES; MACACA MULATTA; MALE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TERMINOLOGY; TIME FACTORS;

EID: 12144291015     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200404000-00013     Document Type: Article

References (37)

1. Belmont MR: Succinylcholine/suxamethonium. Curr Opin Anesth 1995; 8:362-6
2. Durant NN, Katz RL: Suxamethonium. Br J Anaesth 1982; 54:195-208
3. Simpson BR, Savage RM, Foley EI, Ross LA, Strunin L, Walton B, Maxell MP, Harris DM: An azobis-arylimidazopyridinium derivative: A rapidly acting nondepolarizing muscle relaxant. Lancet 1972; 1:516-22
4. Belmont MR, Maehr RB, Wastila WB, Savarese JJ: Pharmacokinetics and pharmacodynamics of benzylisoquinolinium (curare-like) neuromuscular blocking drugs, in Advances in the Use of Muscle Relaxants, Anesthesiology Clinics of North America. Edited by Partridge BL. Philadelphia, WB Saunders, 1993, Vol 11, No 2, pp 272-3
5. Hughes R: Evaluation of the neuromuscular blocking properties and side-effects of the two new isoquinolinium bisquaternary compounds (BW 25264 and BW 403C65). Br J Anaesth 1972; 44:27-42
6. Norman J, Katz RL: Some effects of the steroidal muscle relaxant, dacuronium bromide, in anaesthetized patients. Br J Anaesth 1971; 43:313-9
7. Goudsouzian NG: Rapacuronium and bronchospasm. ANESTHESIOLOGY 2001; 94:727-8
8. Rajchert DM, Pasquariello CA, Watcha MF, Schreiner MS: Rapacuronium and the risk of bronchospasm in pediatric patients. Anesth Analg 2002; 94:488-93
9. Wastila WB, Maehr RB, Turner GL, Hill DA, Savarese JJ: Comparative pharmacology of cisatracurium (51 W89), atracurium, and five isomers in cats. ANESTHESIOLOGY 1996; 85:169-77
10. Savarese JJ, Kitz RJ: The quest for a short-acting nondepolarizing neuromuscular blocking agent. Acta Anaesth Scand Suppl 1973; 53:43-58
11. Hunter JM: The new neuromuscular blocking drugs. N Engl J Med 1995; 332:1691-9
12. Huu-Lainé F, Pinto-Scognamiglio W: Activite curarisante du dichlorure de 3α-bistrimethylammonium 5α-pregnane (malouétine) et de ses stereoisomeres. Arch Int Pharmacodyn 1964; 147:209-19
13. Buckett WR, Marjoribanks CEB, Marwick FA, Morton MB: The pharmacology of pancuronium bromide (ORG NA97), a new potent steroidal neuromuscular blocking agent. Br J Pharmacol 1968; 32:671-82
14. Savage DS, Sleigh T, Carlyle I: The emergence of ORG NC45, 1-[(2β, 3α, 5α, 16β, 17-3,17-bis (acetyloxy)-2(1-piperidinyl)-androstan-16-y1]-1 methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 1980; 52:3S-10S
15. Durant NN, Marshall IG, Savage DS, Nelson DJ, Sleigh T, Carlyle IC: The neuromuscular and autonomic blocking activities of pancuronium, ORG NC45, and other pancuronium analogues in the cat. J Pharm Pharmacol 1979; 31:831-6
16. Wierda JMKH, De Wit APM, Kuizenga K, Agoston S: Clinical observations on the neuromuscular blocking action of ORG 9426, a new steroidal nondepolarizing agent. Br J Anaesth 1990; 64:521-3
17. Bartkowski RR, Witkowski TA, Azad S, Lessin J, Marr A: Rocuronium onset of action: A comparison with atracurium and vecuronium. Anesth Analg 1993; 77:574-8
18. Wright PMC, Brown R, Lau M, Fisher DM: A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. ANESTHESIOLOGY 1999; 90:16-23
19. Wierda JMKH, Van Den Broek L, Proost JH, Verbaan BW, Hennis PJ: Time course of action and intubating conditions of ORG 9487, a new short-acting steroidal muscle relaxant: A comparison with succinylcholine. Anesth Analg 1993; 77:579-84
20. Bowman WC, Rodger IW, Houston J, Marshall RJ, McIndewar I: Structure-action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. ANESTHESIOLOGY 1988; 69:57-62
21. Arden JR, Lynam DP, Castagnoli KP, Canfell PC, Cannon JC, Miller RD: Vecuronium in alcoholic liver disease: A pharmacokinetic and pharmacodynamic analysis. ANESTHESIOLOGY 1988; 68:771-6
22. Szenohradszky J, Caldwell JE, Wright PMC, Brown R, Lan M, Luks AM, Fisher DM: Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide. ANESTHESIOLOGY 1999; 90:24-35
23. Muir AW, Sleigh T, Marshall RJ, Pow E, Anderson KA, Booij LH, Hill DR: Neuromuscular blocking and cardiovascular effects of ORG 9487, a new short-acting aminosteroidal blocking agent, in anaesthetized animals and in isolated muscle preparations. Eur J Anaesthesiol 1998; 15:467-79
24. Tobias JD, Johnson JO, Sprague K, Johnson G: Effects of rapacuronium on respiratory function during general anesthesia. ANESTHESIOLOGY 2001; 95:908-12
25. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. ANESTHESIOLOGY 1998; 88:744-50
26. Jooste E, Klafter F, Hirshman CA, Emala CW: A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. ANESTHESIOLOGY 2003; 98:906-11
27. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U): A short acting nondepolarizing ester neuromuscular blocking drug. ANESTHESIOLOGY 1988; 56:723-32
28. Lien CA, Schmith VD, Embree PB, Belmont MR, Wargin WA, Savarese JJ: The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1994; 80:1296-302
29. Hughes R, Chapple DJ: The pharmacology of atracurium, a new competitive neuromuscular blocking agent. Br J Anaesth 1981; 53:31-44
30. Payne JP, Hughes R: Evaluation of atracurium in anesthetized man. Br J Anaesth 1981; 53:45-54
31. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ: The clinical neuromuscular pharmacology of 51W 89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1995; 82:1139-45
32. Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ: The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. ANESTHESIOLOGY 1984; 61:699-702
33. Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ: Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1996; 84:300-8
34. Welch R, Brown A, Dahl R: In vitro degradation of cisatracurium in Sorensen buffer, rat, and human plasma. Clin Pharmacol Ther 1995; 58:132-4
35. Boros EE, Bigham EC, Boswell GE, Mook RA Jr, Patel SS, Savarese JJ, Ray JA, Thompson JB, Hashim MA, Wisowaty JC, Feldman PL, Samano V: Bis-and mixed-tetrahydroisoquinolinium chlorofumarates; new ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem 1999; 42:206-9
36. Boros EE, Samano V, Ray JA, Thompson JB, Jung DK, Kaldor I, Koble CS, Martin MT, Styles VL, Mook RA Jr, Feldman PL, Savarese JJ, Belmont MR, Bigham EC, Boswell GE, Hashim MA, Patel SS, Wisowaty JC, Bowers GD, Mosely CL, Walsh JS, Reese MJ, Rutkowske RD, Sefler AM, Spitzer TD: Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. J Med Chem 2003; 46:2502-15
37. Savarese JJ, Ali HH, Basta SJ, Scott RPF, Embree PB, Wastila WB, Abou-Donia MM, Gelb C: The cardiovascular effects, of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. ANESTHESIOLOGY 1989; 70:386-94